Flagship Global Corporation, formerly NL One Corporation, is focused on developing and marketing electronic, fiber optic and information technologies. The Company owns the rights to two technologies for healthcare monitoring devices. It focuses on the care and monitoring of patients suffering from diabetes, and requiring ongoing infusion therapy. Its technologies include a Non Invasive Blood Glucose Tester, and a Thermal Detector of Intravenous Infiltration. The Non Invasive Blood Glucose Level Tester focuses on monitoring a patient's blood glucose levels using a non-invasive sensor, preferably taped to a patient's arm. Its technology for thermal detection of intravenous infiltration is in the early development-stage. Its technology, Thermal Detector of Intravenous Infiltration, focuses on employing a plurality of thermo sensors mounted to a patient's skin in an area surrounding and one centimeter away from an intravenous (IV) infusion site and the vein, in which the IV is inserted.